Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

被引：36

作者：

Winston, A

Pozniak, A

Mandalia, S

Gazzard, B

Pillay, D

Nelson, M

机构：

[1] Chelsea & Westminster Hosp, Dept GU & HIV Med, London SW10 9NH, England

[2] Royal Free & UCL, Sch Med, Windeyer Inst, Dept Virol, London W1T 4JF, England

来源：

AIDS | 2004年 / 18卷 / 06期

关键词：

D O I：

10.1097/00002030-200404090-00014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The K65R mutation has been reported to be associated with the use of abacavir, didanosine and tenofovir. With the advent of tenofovir we have assessed the change in the prevalence of this mutation. The prevalence of the K65R mutation remains low, but has significantly increased over a 2-year period. Although not associated with a specific drug, it is associated with the dual use of tenofovir, didanosine and the triple combination of tenofovir, didanosine and abacavir.

引用

页码：949 / 951

页数：3

共 6 条

[1] MUTATED K65R RECOMBINANT REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SHOWS DIMINISHED CHAIN TERMINATION IN THE PRESENCE OF 2',3'-DIDEOXYCYTIDINE 5'-TRIPHOSPHATE AND OTHER DRUGS [J].